Skip to main content

Table 5 Results for all participants recruited outside the pollen season

From: Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study

N users Day 1 Treatment days No treatment days P value*
FF MPAzeFlu MF OAH mono  
99 80 95 275 1299
Symptoms day 1
 Runny nose (%) 72 55 65 71 65 0.03
 Itchy nose (%) 72 53 61 61 53 0.03
 Sneezing (%) 76 49 71 74 67 <0.001
 Nasal congestion (%) 84 63 78 65 62 0.001
 Red eyes (%) 39 21 38 41 36 0.006
 Itchy eyes (%) 55 38 47 62 52 0.04
 Watery eyes (%) 41 29 27 45 34 0.35
Impact of symptoms day 1
 Sleep (%) 47 36 43 35 32 0.17
 Daily activities (%) 46 36 34 37 38 0.54
 Work/school (%) 30 31 24 25 24 0.51
 Bothersome (%) 84 55 68 67 67 <0.001
ARIA score (%)
 0 8 22 19 20 23  
 1 30 38 29 34 31  
 2 23 16 22 21 21 0.06
 3 22 10 22 12 15  
 4 16 14 7 13 11  
 Median [p25-75] 2 [1–3] 1 [1–2] 2 [1–3] 1 [1–3] 1 [0–2] 0.04
VAS global day 1 (%)
 N 99 80 95 275 1299  
 <20 25 29 27 27 41 0.68
 20-49 28 34 33 31 29  
 ≥50 46 38 40 42 30  
 Median [p25-75] 44 [19–67] 34.5 [15–62.5] 46 [17–64] 38 [18–66] 29 [6–54] 0.25
VAS global – all days (%)
 N days 1116 1258 1437 1956 13,120  
 N users 167 128 154 437 1553  
 Average number of days per user± 6.7 9.8 9.3 4.5 8.5  
 <20 50 54 59 50 74 0.0001
 20-49 29 33 27 27 16  
 ≥50 21 13 15 23 10  
 Median [p25-75] 19 [5.5-44] 18 [7–36] 14 [5–34] 19 [5-47] 5 [0-20] 0.18
  1. FF Fluticasone Furoate, MF Mometasone Furoate, MPAzeFlu Azelastine-Fluticasone Propionate
  2. * Comparing MPAzeFlu versus FF or MF. Chi square tests were used for categorical variables (i.e. symptoms and impact of symptoms, ARIA score, global VAS categories); Kruskal–Wallis tests were used for continuous variables (i.e. ARIA score, global VAS)
  3. ± Estimated by dividing the total number of days for which the use of a medication was reported by the total number of users reporting that medication
  4. p25: 25th percentile; p75: 75th percentile